Literature DB >> 21562139

A calcineurin-independent mechanism of angiogenesis inhibition by a nonimmunosuppressive cyclosporin A analog.

Benjamin A Nacev1, Woon-Kai Low, Zhennian Huang, Tina T Su, Zhuang Su, Hisham Alkuraya, Dan Kasuga, Woong Sun, Mario Träger, Manfred Braun, Gunter Fischer, Kang Zhang, Jun O Liu.   

Abstract

Cyclosporin A (CsA) is a widely used immunosuppressant drug. Its immunosuppressive activity occurs through the inhibition of the protein phosphatase calcineurin via formation of a ternary complex with cyclophilin A (CypA). CsA also inhibits endothelial cell proliferation and angiogenesis. This has been thought to occur through calcineurin inhibition as well. However, CsA is also a potent inhibitor of cyclophilins, a class of prolyl isomerases. Because calcineurin inhibition requires binding, and therefore inhibition of CypA, the relative contributions of calcineurin and cyclophilin inhibition in antiangiogenesis have not been addressed. We have taken a chemical biology approach to explore this question by dissociating the two activities of CsA at the molecular level. We have identified a nonimmunosuppressive analog of CsA that does not inhibit calcineurin but maintains inhibition of endothelial cell proliferation and in vivo angiogenesis. The same analog also maintains inhibition of all cyclophilin isoforms tested. We also show that a second, structurally distinct, cyclophilin inhibitor is sufficient to block endothelial cell proliferation. These results suggest that the inhibition of cyclophilins may play a larger role in the antiangiogenic activity of CsA than previously believed, and that cyclophilins may be potential antiangiogenic drug targets.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21562139      PMCID: PMC3141903          DOI: 10.1124/jpet.111.180851

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  39 in total

1.  A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor.

Authors:  A Passaniti; R M Taylor; R Pili; Y Guo; P V Long; J A Haney; R R Pauly; D S Grant; G R Martin
Journal:  Lab Invest       Date:  1992-10       Impact factor: 5.662

2.  Corneal neovascularization induced by xenografts or chemical cautery. Inhibition by cyclosporin A.

Authors:  U Benelli; J R Ross; M Nardi; G K Klintworth
Journal:  Invest Ophthalmol Vis Sci       Date:  1997-02       Impact factor: 4.799

Review 3.  Transcription factors of the NFAT family: regulation and function.

Authors:  A Rao; C Luo; P G Hogan
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

4.  Apoptosis of T cells mediated by Ca2+-induced release of the transcription factor MEF2.

Authors:  H D Youn; L Sun; R Prywes; J O Liu
Journal:  Science       Date:  1999-10-22       Impact factor: 47.728

5.  Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death.

Authors:  Takashi Nakagawa; Shigeomi Shimizu; Tetsuya Watanabe; Osamu Yamaguchi; Kinya Otsu; Hirotaka Yamagata; Hidenori Inohara; Takeshi Kubo; Yoshihide Tsujimoto
Journal:  Nature       Date:  2005-03-31       Impact factor: 49.962

6.  NFATc1 mediates vascular endothelial growth factor-induced proliferation of human pulmonary valve endothelial cells.

Authors:  Ehrin N Johnson; You Mie Lee; Tara L Sander; Elena Rabkin; Frederick J Schoen; Sunjay Kaushal; Joyce Bischoff
Journal:  J Biol Chem       Date:  2002-11-09       Impact factor: 5.157

Review 7.  Lessons from phase III clinical trials on anti-VEGF therapy for cancer.

Authors:  Rakesh K Jain; Dan G Duda; Jeffrey W Clark; Jay S Loeffler
Journal:  Nat Clin Pract Oncol       Date:  2006-01

Review 8.  Calmodulin-dependent phosphatase, kinases, and transcriptional corepressors involved in T-cell activation.

Authors:  Jun O Liu
Journal:  Immunol Rev       Date:  2009-03       Impact factor: 12.988

Review 9.  Mitochondrial permeability transition: a common pathway to necrosis and apoptosis.

Authors:  Jae-Sung Kim; Lihua He; John J Lemasters
Journal:  Biochem Biophys Res Commun       Date:  2003-05-09       Impact factor: 3.575

10.  Regulation of nuclear factor of activated T cells (NFAT) in vascular endothelial cells.

Authors:  Andreas Rinne; Kathrin Banach; Lothar A Blatter
Journal:  J Mol Cell Cardiol       Date:  2009-06-21       Impact factor: 5.000

View more
  6 in total

1.  Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling.

Authors:  Wei Shi; Benjamin A Nacev; Blake T Aftab; Sarah Head; Charles M Rudin; Jun O Liu
Journal:  J Med Chem       Date:  2011-10-05       Impact factor: 7.446

2.  The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking, and signaling in endothelial cells.

Authors:  Benjamin A Nacev; Paola Grassi; Anne Dell; Stuart M Haslam; Jun O Liu
Journal:  J Biol Chem       Date:  2011-10-24       Impact factor: 5.157

Review 3.  Current update on theranostic roles of cyclophilin A in kidney diseases.

Authors:  Sudarat Hadpech; Visith Thongboonkerd
Journal:  Theranostics       Date:  2022-05-13       Impact factor: 11.600

4.  Drug Modulators of B Cell Signaling Pathways and Epstein-Barr Virus Lytic Activation.

Authors:  John G Kosowicz; Jaeyeun Lee; Brandon Peiffer; Zufeng Guo; Jianmeng Chen; Gangling Liao; S Diane Hayward; Jun O Liu; Richard F Ambinder
Journal:  J Virol       Date:  2017-07-27       Impact factor: 5.103

5.  Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazole.

Authors:  Benjamin A Nacev; Jun O Liu
Journal:  PLoS One       Date:  2011-09-28       Impact factor: 3.240

6.  Cyclosporin a disrupts notch signaling and vascular lumen maintenance.

Authors:  Raghav Pandey; Mark A Botros; Benjamin A Nacev; Allan R Albig
Journal:  PLoS One       Date:  2015-03-16       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.